Liver support technology – an update
Author:
- 22 August 2006
- journal article
- review article
- Published by Wiley in Xenotransplantation
- Vol. 13 (5) , 380-389
Abstract
Abstract: Background: Currently, there is no direct treatment for hepatic failure, and patients must receive a transplant or endure prolonged hospitalization, with significant morbidity and mortality. Because of the scarcity of donor organs, liver support strategies are being developed with the aim of either supporting patients with borderline functional liver cell mass until an appropriate organ becomes available for transplantation or until their livers recover from injury.Methods: A literature review was performed using MEDLINE and library searches. Only major blood detoxification/purification devices and cell‐based techniques are included in this review.Results: Currently, a number of blood purification systems and devices utilizing viable liver cells are in various stages of clinical development. Non‐biological systems include plasma exchange, albumin dialysis, hemo(dia)filtration, and sorbent‐based devices (charcoal, resin). These systems are able to remove toxins of hepatic failure, and their utility is limited by their inability to provide missing liver‐specific functions. In contrast, hepatocyte‐based devices are able to provide whole liver functions, including detoxification, biosynthesis, and biotransformation. Molecular adsorbent recycling system (MARS) blood detoxification system has been tested in thousands of patients, but additional well‐conducted controlled studies are warranted to better define the role of MARS® in the treatment of patients with acute hepatic failure and acute exacerbation of chronic liver disease. HepatAssist™ was tested in a phase II/III controlled clinical trial that demonstrated safety and proof of concept for use of biological liver support systems to improve patient survival in acute hepatic failure.Conclusions: Developing an effective liver assist technology has proven difficult, because of the complexity of liver functions that must be replaced, as well as heterogeneity of the patient population. Non‐biological systems may have a role in the treatment of specific forms of liver failure where the primary goal is to provide blood detoxification/purification. Biological systems appear to be useful in treating liver failure where the primary objective is to provide whole liver functions which are impaired or lost. It is suggested that there will be a role for hybrid liver support systems that offer liver cell therapy and various forms of blood purification (sorption, hemofiltration and diafiltration) to treat patients with specific forms of liver failure at various stages of their illness.Keywords
This publication has 54 references indexed in Scilit:
- A Novel Plasma Filtration Therapy for Hepatic Failure: Preclinical StudiesTherapeutic Apheresis and Dialysis, 2006
- Prometheus® – a new extracorporeal system for the treatment of liver failure☆Journal of Hepatology, 2003
- Molecular Adsorbent Recycling System (MARS): Clinical Results of a New Membrane‐Based Blood Purification System for Bioartificial Liver SupportArtificial Organs, 1999
- THE FRACTIONATED PLASMA SEPARATION AND ADSORPTION SYSTEM: IN VITRO EVALUATION AND FIRST CLINICAL RESULTSASAIO Journal, 1999
- Fulminant Hepatic Failure in Rats: Survival and Effect on Blood Chemistry and Liver RegenerationHepatology, 1996
- THE USE OF ABO-INCOMPATIBLE GRAFTS IN LIVER TRANSPLANTATIONTransplantation, 1995
- Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failureThe Lancet, 1993
- Development of a Hybrid Bioartificial LiverAnnals of Surgery, 1993
- The Application of Immobilized Enzymes in an Artificial Liver Support SystemArtificial Organs, 1979
- Plasmapheresis with plasma exchange in hepatic coma. II. Fulminant viral hepatitis as a systemic diseaseArchives of internal medicine (1960), 1972